Re­org com­ing for lit­tle biotech as it shut­ters PhII ra­dioim­munother­a­py tri­al on un­der­whelm­ing da­ta

Af­ter de­cid­ing that its ra­dioim­munother­a­py no longer has a vi­able path to com­mer­cial­iza­tion, Nor­way’s Nordic Nanovec­tor is shut­ting down its lead and on­ly clin­i­cal tri­al.

As a re­sult, the com­pa­ny says it will al­so im­ple­ment a re­struc­tur­ing “with the pur­pose of re­duc­ing costs where nec­es­sary to en­able sup­port of es­sen­tial ac­tiv­i­ties as­so­ci­at­ed with de­vel­op­ment of the pipeline.”

Chair­man Jan Eg­berts called the de­ci­sion “ex­treme­ly dis­ap­point­ing” for all in­volved.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER